2. Lipids
  3. Saccharolipids

Saccharolipids

Saccharolipids (12):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112174
    UDP-GlcNAc disodium 91183-98-1 99.92%
    UDP-GlcNAc Disodium Salt (UDP-α-D-N-Acetylglucosamine Disodium Salt) is a donor substrate of O-GlcNAc transferase (OGT).
    UDP-GlcNAc disodium
  • HY-N8515C
    UDP-3-O-acyl-GlcNAc disodium
    UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) disodium is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc disodium
  • HY-N8515
    UDP-3-O-acyl-GlcNAc 108636-29-9
    UDP-3-O-acyl-GlcNAc (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine) is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc
  • HY-W585865
    UDP-3-O-acyl-GlcNAc Tris 112710-84-6
    UDP-3-O-acyl-GlcNAc Tris (UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine Tris) serves as a deacetylation substrate and biosynthetic intermediate in the biosynthetic pathways of lipid A and Kdo2-lipid A in Escherichia coli. UDP-3-O-acyl-GlcNAc Tris undergoes enzymatic deacetylation via LpxC to produce UDP-3-O-[(R)-3-hydroxymyristoyl]glucosamine and release acetate. UDP-3-O-acyl-GlcNAc Tris accumulates in Escherichia coli extracts in the absence of [(R)-3-hydroxymyristoyl]-acyl carrier protein. UDP-3-O-acyl-GlcNAc Tris can be used in studies related to Gram-negative shock.
    UDP-3-O-acyl-GlcNAc Tris
  • HY-N8515B
    UDP-3-O-acyl-GlcNAc diammonium
    UDP-3-O-acyl-GlcNAc diammonium is an E. coli metabolite that is involved in 3-deoxy-D-manno-octulosonate (KDO) biosynthesis pathway.
    UDP-3-O-acyl-GlcNAc diammonium
  • HY-W127355
    Kdo2-Lipid A 123621-04-5
    Kdo2-Lipid A is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Kdo2-Lipid A
  • HY-179810
    18:1 MGDG (synthetic) 33600-46-3
    18:1 MGDG is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    18:1 MGDG (synthetic)
  • HY-179744
    18:2 MGDG (synthetic) 88195-88-4
    18:2 MGDG (synthetic) is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.
    18:2 MGDG (synthetic)
  • HY-N16344
    Hydrogenated DGDG 960204-99-3
    Hydrogenated DGDG is a lipid derived from plants. Digalactosyldiacylglycerol (DGDG) is a galactosylglycerolipid, which is a major lipid component in the thylakoid membrane of leaf chloroplasts. DGDG is vital for photosynthesis.
    Hydrogenated DGDG
  • HY-N16337
    Hydrogenated MGDG 51424-47-6
    Hydrogenated MGDG is a type of glycolipid. Monogalactosyldiacylglycerol (MGDG), a galactosylglycerolipid, is a major lipid in the thylakoid membrane of the chloroplast of leaves. It is also localized in the roots, fruits and grains. MGDG is synthesized from Monogalactosyldiacylglycerol synthase 1 (MGD1). It is a precursor for digalactosyldiacylglycerol (DGDG).
    Hydrogenated MGDG
  • HY-148596
    UDP-GlcNAc 528-04-1
    UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y14 receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections.
    UDP-GlcNAc
  • HY-130581
    Lipid X 86559-73-1
    Lipid X is a 2,3-diacylglucosamine-1-phosphate that serves as the monosaccharide precursor of lipid A, possessing both LPS antagonist and weak agonist activities. Lipid X exerts protective effects by inhibiting tumor necrosis factor production, monocyte procoagulant activity, and neutrophil priming. Lipid X may induce transient pulmonary hypertension, neutropenia, and mild pyrogenic effects in laboratory animals. Lipid X has low toxicity and no in vitro antibacterial activity, but it significantly reduces mortality following Gram-negative bacterial infection and endotoxin exposure. Lipid X tends to accumulate in liver tissue, binds to circulating cellular components, and can be converted to lipid Y through transesterification. Lipid X can be used in research on Gram-negative bacterial sepsis, endotoxemia, and associated pulmonary hypertension.
    Lipid X